PLYX is currently priced at $2.30. The technical outlook is "Sell" based on moving average alignment, RSI, and MACD signals.
Technical & fundamental data as of Jun 10, 2026.
Open?$2.30
High?$2.30
Low?$2.30
Prev. Close?$2.28
Volume?811
Avg. Volume?N/A
VWAP?$2.30
Bid / Ask
Bid?$1.96 × 100
Ask?$2.72 × 100
Spread?$0.76
Midpoint?$2.34
Valuation & Ratios
Market Cap?113.6M
Shares Out?47.3M
Float?9.8M
Float %?20.7%
P/E Ratio?N/A
P/B Ratio?N/A
EPS?N/A
Dividend?N/A
Ex-Dividend?N/A
News
Profile
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.